NetScientific announced on Thursday that its portfolio company, ProAxsis, has secured the first sale of NEATstik to a research laboratory conducting a respiratory clinical trial. The product, which was registered with a CE mark in late 2017, utilises the company's ProteaseTag technology to allow the qualitative measurement of the active form of neutrophil elastase, an established biomarker of lung infection and inflammation. Francois Martelet, chief executive of NetScientific, said: "We are very ...Den vollständigen Artikel lesen ...